BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Burny W, Callegaro A, Bechtold V, Clement F, Delhaye S, Fissette L, Janssens M, Leroux-Roels G, Marchant A, van den Berg RA, Garçon N, van der Most R, Didierlaurent AM; ECR-002 Study Group. Different Adjuvants Induce Common Innate Pathways That Are Associated with Enhanced Adaptive Responses against a Model Antigen in Humans. Front Immunol 2017;8:943. [PMID: 28855902 DOI: 10.3389/fimmu.2017.00943] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Pulendran B, S Arunachalam P, O'Hagan DT. Emerging concepts in the science of vaccine adjuvants. Nat Rev Drug Discov 2021;20:454-75. [PMID: 33824489 DOI: 10.1038/s41573-021-00163-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 20] [Article Influence: 13.0] [Reference Citation Analysis]
2 De Mot L, Bechtold V, Bol V, Callegaro A, Coccia M, Essaghir A, Hasdemir D, Ulloa-montoya F, Siena E, Smilde A, van den Berg RA, Didierlaurent AM, Burny W, van der Most RG. Transcriptional profiles of adjuvanted hepatitis B vaccines display variable interindividual homogeneity but a shared core signature. Sci Transl Med 2020;12:eaay8618. [DOI: 10.1126/scitranslmed.aay8618] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
3 Hwang YH, Song KH, Choi Y, Go S, Choi SJ, Jung J, Kang CK, Choe PG, Kim NJ, Park WB, Oh MD. Can reactogenicity predict immunogenicity after COVID-19 vaccination? Korean J Intern Med 2021;36:1486-91. [PMID: 34038996 DOI: 10.3904/kjim.2021.210] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
4 Weiss C, Carriere M, Fusco L, Capua I, Regla-Nava JA, Pasquali M, Scott JA, Vitale F, Unal MA, Mattevi C, Bedognetti D, Merkoçi A, Tasciotti E, Yilmazer A, Gogotsi Y, Stellacci F, Delogu LG. Toward Nanotechnology-Enabled Approaches against the COVID-19 Pandemic. ACS Nano 2020;14:6383-406. [PMID: 32519842 DOI: 10.1021/acsnano.0c03697] [Cited by in Crossref: 277] [Cited by in F6Publishing: 226] [Article Influence: 138.5] [Reference Citation Analysis]
5 Harandi AM. Systems analysis of human vaccine adjuvants. Semin Immunol 2018;39:30-4. [PMID: 30122362 DOI: 10.1016/j.smim.2018.08.001] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
6 Laupèze B, Hervé C, Di Pasquale A, Tavares Da Silva F. Adjuvant Systems for vaccines: 13 years of post-licensure experience in diverse populations have progressed the way adjuvanted vaccine safety is investigated and understood. Vaccine 2019;37:5670-80. [PMID: 31420171 DOI: 10.1016/j.vaccine.2019.07.098] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
7 Goyal G, Prabhala P, Mahajan G, Bausk B, Gilboa T, Xie L, Zhai Y, Lazarovits R, Mansour A, Kim MS, Patil A, Curran D, Long JM, Sharma S, Junaid A, Cohen L, Ferrante TC, Levy O, Prantil-Baun R, Walt DR, Ingber DE. Ectopic Lymphoid Follicle Formation and Human Seasonal Influenza Vaccination Responses Recapitulated in an Organ-on-a-Chip. Adv Sci (Weinh) 2022;9:e2103241. [PMID: 35289122 DOI: 10.1002/advs.202103241] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
8 Du Y, Thompson EG, Muller J, Valvo J, Braun J, Shankar S, van den Berg RA, Jongert E, Dover D, Sadoff J, Hendriks J, Gardner MJ, Ballou WR, Regules JA, van der Most R, Aderem A, Ockenhouse CF, Hill AV, Wille-Reece U, Zak DE. The Ratiometric Transcript Signature MX2/GPR183 Is Consistently Associated With RTS,S-Mediated Protection Against Controlled Human Malaria Infection. Front Immunol 2020;11:669. [PMID: 32411130 DOI: 10.3389/fimmu.2020.00669] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
9 Van Maele L, Fougeron D, Cayet D, Chalon A, Piccioli D, Collignon C, Sirard JC, Didierlaurent AM. Toll-like receptor 4 signaling in hematopoietic-lineage cells contributes to the enhanced activity of the human vaccine adjuvant AS01. Eur J Immunol 2019;49:2134-45. [PMID: 31489613 DOI: 10.1002/eji.201948234] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
10 Joshi G, Borah P, Thakur S, Sharma P, Mayank, Poduri R. Exploring the COVID-19 vaccine candidates against SARS-CoV-2 and its variants: where do we stand and where do we go? Hum Vaccin Immunother 2021;:1-27. [PMID: 34856868 DOI: 10.1080/21645515.2021.1995283] [Reference Citation Analysis]
11 Burny W, Hervé C, Caubet M, Yarzabal JP, Didierlaurent AM. Utility of urinary cytokine levels as predictors of the immunogenicity and reactogenicity of AS01-adjuvanted hepatitis B vaccine in healthy adults. Vaccine 2022:S0264-410X(22)00361-9. [PMID: 35367070 DOI: 10.1016/j.vaccine.2022.03.050] [Reference Citation Analysis]
12 Weiner J, Lewis DJM, Maertzdorf J, Mollenkopf HJ, Bodinham C, Pizzoferro K, Linley C, Greenwood A, Mantovani A, Bottazzi B, Denoel P, Leroux-Roels G, Kester KE, Jonsdottir I, van den Berg R, Kaufmann SHE, Del Giudice G. Characterization of potential biomarkers of reactogenicity of licensed antiviral vaccines: randomized controlled clinical trials conducted by the BIOVACSAFE consortium. Sci Rep 2019;9:20362. [PMID: 31889148 DOI: 10.1038/s41598-019-56994-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
13 Wilkins AL, Kazmin D, Napolitani G, Clutterbuck EA, Pulendran B, Siegrist CA, Pollard AJ. AS03- and MF59-Adjuvanted Influenza Vaccines in Children. Front Immunol 2017;8:1760. [PMID: 29326687 DOI: 10.3389/fimmu.2017.01760] [Cited by in Crossref: 57] [Cited by in F6Publishing: 52] [Article Influence: 11.4] [Reference Citation Analysis]
14 [DOI: 10.1101/806505] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
15 Del Giudice G, Rappuoli R, Didierlaurent AM. Correlates of adjuvanticity: A review on adjuvants in licensed vaccines. Seminars in Immunology 2018;39:14-21. [DOI: 10.1016/j.smim.2018.05.001] [Cited by in Crossref: 222] [Cited by in F6Publishing: 202] [Article Influence: 55.5] [Reference Citation Analysis]
16 Pillet S, Arunachalam PS, Andreani G, Golden N, Fontenot J, Aye PP, Röltgen K, Lehmicke G, Gobeil P, Dubé C, Trépanier S, Charland N, D'Aoust MA, Russell-Lodrigue K, Monjure C, Blair RV, Boyd SD, Bohm RP, Rappaport J, Villinger F, Landry N, Pulendran B, Ward BJ. Safety, immunogenicity, and protection provided by unadjuvanted and adjuvanted formulations of a recombinant plant-derived virus-like particle vaccine candidate for COVID-19 in nonhuman primates. Cell Mol Immunol 2022;19:222-33. [PMID: 34983950 DOI: 10.1038/s41423-021-00809-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
17 Burny W, Marchant A, Hervé C, Callegaro A, Caubet M, Fissette L, Gheyle L, Legrand C, Ndour C, Tavares Da Silva F, van der Most R, Willems F, Didierlaurent AM, Yarzabal J; ECR-008 study group. Inflammatory parameters associated with systemic reactogenicity following vaccination with adjuvanted hepatitis B vaccines in humans. Vaccine 2019;37:2004-15. [PMID: 30850240 DOI: 10.1016/j.vaccine.2019.02.015] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
18 Garcia-Pintos C, Riet-Correa F, Menchaca A. Effect of Foot-and-Mouth Disease Vaccine on Pregnancy Failure in Beef Cows. Front Vet Sci 2021;8:761304. [PMID: 34869734 DOI: 10.3389/fvets.2021.761304] [Reference Citation Analysis]
19 Lofano G, Mallett CP, Bertholet S, O'Hagan DT. Technological approaches to streamline vaccination schedules, progressing towards single-dose vaccines. NPJ Vaccines 2020;5:88. [PMID: 33024579 DOI: 10.1038/s41541-020-00238-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
20 Lambert PH, Ambrosino DM, Andersen SR, Baric RS, Black SB, Chen RT, Dekker CL, Didierlaurent AM, Graham BS, Martin SD, Molrine DC, Perlman S, Picard-Fraser PA, Pollard AJ, Qin C, Subbarao K, Cramer JP. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines. Vaccine 2020;38:4783-91. [PMID: 32507409 DOI: 10.1016/j.vaccine.2020.05.064] [Cited by in Crossref: 65] [Cited by in F6Publishing: 60] [Article Influence: 32.5] [Reference Citation Analysis]
21 O'Hagan DT, van der Most R, Lodaya RN, Coccia M, Lofano G. "World in motion" - emulsion adjuvants rising to meet the pandemic challenges. NPJ Vaccines 2021;6:158. [PMID: 34934069 DOI: 10.1038/s41541-021-00418-0] [Reference Citation Analysis]
22 Raponi A, Brewer JM, Garside P, Laera D. Nanoalum adjuvanted vaccines: small details make a big difference. Semin Immunol 2021;:101544. [PMID: 34895823 DOI: 10.1016/j.smim.2021.101544] [Reference Citation Analysis]
23 Sarkar I, Garg R, van Drunen Littel-van den Hurk S. Selection of adjuvants for vaccines targeting specific pathogens. Expert Rev Vaccines 2019;18:505-21. [PMID: 31009255 DOI: 10.1080/14760584.2019.1604231] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
24 Coggins SA, Laing ED, Olsen CH, Goguet E, Moser M, Jackson-Thompson BM, Samuels EC, Pollett SD, Tribble DR, Davies J, Illinik L, Hollis-Perry M, Maiolatesi SE, Duplessis CA, Ramsey KF, Reyes AE, Alcorta Y, Wong MA, Wang G, Ortega O, Parmelee E, Lindrose AR, Snow AL, Malloy AMW, Letizia AG, Ewing D, Powers JH, Schully KL, Burgess TH, Broder CC, Mitre E. Adverse Effects and Antibody Titers in Response to the BNT162b2 mRNA COVID-19 Vaccine in a Prospective Study of Healthcare Workers. Open Forum Infect Dis 2022;9:ofab575. [PMID: 35047649 DOI: 10.1093/ofid/ofab575] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Orr MT, Khandhar AP, Seydoux E, Liang H, Gage E, Mikasa T, Beebe EL, Rintala ND, Persson KH, Ahniyaz A, Carter D, Reed SG, Fox CB. Reprogramming the adjuvant properties of aluminum oxyhydroxide with nanoparticle technology. NPJ Vaccines 2019;4:1. [PMID: 30622742 DOI: 10.1038/s41541-018-0094-0] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 9.0] [Reference Citation Analysis]
26 Olivier CE. The use of Allergoids and Adjuvants in Allergen Immunotherapy. Arch Asthma Allergy Immunol 2017;1:040-60. [DOI: 10.29328/journal.haard.1001006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
27 Laupèze B, Del Giudice G, Doherty MT, Van der Most R. Vaccination as a preventative measure contributing to immune fitness. NPJ Vaccines 2021;6:93. [PMID: 34315886 DOI: 10.1038/s41541-021-00354-z] [Reference Citation Analysis]
28 Hervé C, Laupèze B, Del Giudice G, Didierlaurent AM, Tavares Da Silva F. The how's and what's of vaccine reactogenicity. NPJ Vaccines 2019;4:39. [PMID: 31583123 DOI: 10.1038/s41541-019-0132-6] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 15.3] [Reference Citation Analysis]
29 Nellore A, Mannon RB, Limaye AP. Letter to the Editor. Clin Infect Dis 2020;70:719. [PMID: 31340381 DOI: 10.1093/cid/ciz495] [Reference Citation Analysis]
30 O'Hagan DT, Lodaya RN, Lofano G. The continued advance of vaccine adjuvants - 'we can work it out'. Semin Immunol 2020;50:101426. [PMID: 33257234 DOI: 10.1016/j.smim.2020.101426] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
31 Held J, Esse J, Tascilar K, Steininger P, Schober K, Irrgang P, Alsalameh R, Tenbusch M, Seggewies C, Bogdan C. Reactogenicity Correlates Only Weakly with Humoral Immunogenicity after COVID-19 Vaccination with BNT162b2 mRNA (Comirnaty®). Vaccines (Basel) 2021;9:1063. [PMID: 34696171 DOI: 10.3390/vaccines9101063] [Reference Citation Analysis]
32 Sameshima T, Maeda Y, Mukai T, Goto M. Altered cytokine profiles in relapsed paucibacillary leprosy: a case report. BMC Infect Dis 2021;21:1155. [PMID: 34774006 DOI: 10.1186/s12879-021-06836-8] [Reference Citation Analysis]
33 Ferraro A, Buonocore SM, Auquier P, Nicolas I, Wallemacq H, Boutriau D, van der Most RG. Role and plasticity of Th1 and Th17 responses in immunity to Staphylococcus aureus. Hum Vaccin Immunother 2019;15:2980-92. [PMID: 31149870 DOI: 10.1080/21645515.2019.1613126] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
34 Lu G, Zhou J, Zhao YH, Wang L. DNA vaccine ROP29 from Toxoplasma gondii containing R848 enhances protective immunity in mice. Parasite Immunol 2018;40:e12578. [PMID: 30091162 DOI: 10.1111/pim.12578] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
35 HogenEsch H, O'Hagan DT, Fox CB. Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want. NPJ Vaccines 2018;3:51. [PMID: 30323958 DOI: 10.1038/s41541-018-0089-x] [Cited by in Crossref: 106] [Cited by in F6Publishing: 107] [Article Influence: 26.5] [Reference Citation Analysis]
36 Lee A, Wimmers F, Pulendran B. Epigenetic adjuvants: durable reprogramming of the innate immune systemsy with adjuvants. Curr Opin Immunol 2022;77:102189. [PMID: 35588691 DOI: 10.1016/j.coi.2022.102189] [Reference Citation Analysis]
37 Budroni S, Buricchi F, Cavallone A, Volpini G, Mariani A, Lo Surdo P, Blohmke CJ, Del Giudice G, Medini D, Finco O. Computational modeling of microfluidic data provides high-throughput affinity estimates for monoclonal antibodies. Comput Struct Biotechnol J 2021;19:3664-72. [PMID: 34257845 DOI: 10.1016/j.csbj.2021.06.024] [Reference Citation Analysis]
38 Coggins SAA, Laing ED, Olsen CH, Goguet E, Moser M, Jackson-Thompson BM, Samuels EC, Pollett SD, Tribble DR, Davies J, Illinik L, Hollis-Perry M, Maiolatesi SE, Duplessis CA, Ramsey KF, Reyes AE, Alcorta Y, Wong MA, Wang G, Ortega O, Parmelee E, Lindrose AR, Snow AL, Malloy AMW, Letizia AG, Powers JH, Burgess TH, Broder CC, Mitre E. Adverse effects and antibody titers in response to the BNT162b2 mRNA COVID-19 vaccine in a prospective study of healthcare workers. medRxiv 2021:2021. [PMID: 34230937 DOI: 10.1101/2021.06.25.21259544] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
39 Nanishi E, Dowling DJ, Levy O. Toward precision adjuvants: optimizing science and safety. Curr Opin Pediatr 2020;32:125-38. [PMID: 31904601 DOI: 10.1097/MOP.0000000000000868] [Cited by in Crossref: 25] [Cited by in F6Publishing: 15] [Article Influence: 12.5] [Reference Citation Analysis]
40 Baccili CC, Martin CC, Decaris N, Madureira KM, Chase C, Gomes V. Effects of 3 Different Commercial Vaccines Formulations against BVDV and BHV-1 on the Inflammatory Response of Holstein Heifers. Vet Sci 2019;6:E69. [PMID: 31455017 DOI: 10.3390/vetsci6030069] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
41 Callegaro A, Burny W, Hervé C, Kim JH, Levin MJ, Zahaf T, Cunningham AL, Didierlaurent AM. Association between immunogenicity and reactogenicity: a post hoc analysis of two Phase 3 studies with the adjuvanted recombinant zoster vaccine. J Infect Dis 2021:jiab536. [PMID: 34662415 DOI: 10.1093/infdis/jiab536] [Reference Citation Analysis]
42 Tregoning JS, Russell RF, Kinnear E. Adjuvanted influenza vaccines. Hum Vaccin Immunother 2018;14:550-64. [PMID: 29232151 DOI: 10.1080/21645515.2017.1415684] [Cited by in Crossref: 103] [Cited by in F6Publishing: 93] [Article Influence: 25.8] [Reference Citation Analysis]
43 Howard LM, Goll JB, Jensen TL, Hoek KL, Prasad N, Gelber CE, Levy SE, Joyce S, Link AJ, Creech CB, Edwards KM. AS03-Adjuvanted H5N1 Avian Influenza Vaccine Modulates Early Innate Immune Signatures in Human Peripheral Blood Mononuclear Cells. J Infect Dis 2019;219:1786-98. [PMID: 30566602 DOI: 10.1093/infdis/jiy721] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
44 Endo M, Tanishima M, Ibaragi K, Hayashida K, Fukuda T, Tanabe T, Naruse T, Kino Y, Ueda K. Clinical phase II and III studies of an AS03-adjuvanted H5N1 influenza vaccine produced in an EB66® cell culture platform. Influenza Other Respir Viruses 2020;14:551-63. [PMID: 32579785 DOI: 10.1111/irv.12755] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
45 Seydoux E, Liang H, Dubois Cauwelaert N, Archer M, Rintala ND, Kramer R, Carter D, Fox CB, Orr MT. Effective Combination Adjuvants Engage Both TLR and Inflammasome Pathways To Promote Potent Adaptive Immune Responses. J Immunol 2018;201:98-112. [PMID: 29769270 DOI: 10.4049/jimmunol.1701604] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 5.3] [Reference Citation Analysis]
46 Vizcarra P, Haemmerle J, Velasco H, Velasco T, Fernández-Escribano M, Vallejo A, Casado JL. BNT162b2 mRNA COVID-19 vaccine Reactogenicity: The key role of immunity. Vaccine 2021;39:7367-74. [PMID: 34802792 DOI: 10.1016/j.vaccine.2021.10.074] [Reference Citation Analysis]
47 Wimmers F, Donato M, Kuo A, Ashuach T, Gupta S, Li C, Dvorak M, Foecke MH, Chang SE, Hagan T, De Jong SE, Maecker HT, van der Most R, Cheung P, Cortese M, Bosinger SE, Davis M, Rouphael N, Subramaniam S, Yosef N, Utz PJ, Khatri P, Pulendran B. The single-cell epigenomic and transcriptional landscape of immunity to influenza vaccination. Cell 2021;184:3915-3935.e21. [PMID: 34174187 DOI: 10.1016/j.cell.2021.05.039] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
48 Rappuoli R, Hanon E. Sustainable vaccine development: a vaccine manufacturer's perspective. Curr Opin Immunol 2018;53:111-8. [PMID: 29751212 DOI: 10.1016/j.coi.2018.04.019] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
49 Kang YM, Lim J, Choe KW, Lee KD, Jo DH, Kim MJ, Kim JM, Kim KN. Reactogenicity after the first and second doses of BNT162b2 mRNA coronavirus disease vaccine: a single-center study. Clin Exp Vaccine Res 2021;10:282-9. [PMID: 34703812 DOI: 10.7774/cevr.2021.10.3.282] [Reference Citation Analysis]
50 Budroni S, Buricchi F, Cavallone A, Bourguignon P, Caubet M, Dewar V, D'Oro U, Finco O, Garçon N, El Idrissi M, Janssens M, Leroux-Roels G, Marchant A, Schwarz T, Van Damme P, Volpini G, van der Most R, Didierlaurent AM, Burny W. Antibody avidity, persistence, and response to antigen recall: comparison of vaccine adjuvants. NPJ Vaccines 2021;6:78. [PMID: 34021167 DOI: 10.1038/s41541-021-00337-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
51 Voutssas-Lara J, Cervantes-Torres J, Hernández M, Bobes RJ, Lamoyi E, Vázquez-Ramírez RA, Mendoza L, Reyes-Barrera KL, López-Martínez R, Alpuche-Solís ÁG, Rosales-Mendoza S, Huerta L, Fragoso G, Sciutto E. Influence of adjuvants on the amount, specificity and functional activity of antibody response to human influenza vaccine in mice. Mol Immunol 2021;135:398-407. [PMID: 34022515 DOI: 10.1016/j.molimm.2021.05.003] [Reference Citation Analysis]